Abstract
We examined the inhibitory effect of heparin on vascular smooth muscle cell (VSMC) outgrowth from cultured coronary artery explants of primary atherosclerotic lesions and of undiseased regions from the same patients, compared with explant outgrowth from control patients (idiopathic cardiomyopathy) with no evidence of atherosclerosis. For undiseased tissue regardless of origin, heparin significantly delayed half-maximum percentage explant outgrowth time (mean difference from control treatment 2·1 [SE 0 8] days for atherosclerosis patients and 2 3 [10] days for control patients). For plaque tissue, heparin had no such effect. Thus the proliferative state of the cells involved in outgrowth may influence the activity of heparin.
| Original language | English |
|---|---|
| Pages (from-to) | 97-98 |
| Number of pages | 2 |
| Journal | The Lancet |
| Volume | 344 |
| Issue number | 8915 |
| DOIs | |
| Publication status | Published - 9 Jul 1994 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Inhibition of human vascular smooth muscle cell growth by heparin'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver